HomeAbout UsContact Us1-800-477-6037
Medical Device Daily
Archive Search

User ID


Forgot password

Remember my login

New User ?

Products & Services
Medical Device Daily
Medtech Resources
BioWorld Executive Compensation Report 2014
MDD State of the Industry Report 2013
BioWorld and Medical Device VC Directory 2012
MDD Perspectives
BioWorld Today
Biotech Resources
Perspectives Blog
PMA and 501(k) Approvals

Today's Issue of Medical Device Daily

Wednesday, June 29, 2016

Today's Headlines

Caredx pushes back against CMS' steep proposed 74% Allomap test price cut

Molecular diagnostics company Caredx Inc. said it will not be able to provide Allomap tests to Medicare patients if a 74 percent reimbursement cut stands. The blood test is used to determine rejection risk in heart transplant recipients and, according to the company, it is the only alternative to the more invasive and riskier biopsy procedure.

Will innovation pay the price for med-tech biggering?

The urge to go on biggering and biggering and biggering has taken over the med-tech world. Barely a year after Zimmer and Biomet completed a $14 billion merger to become the second largest orthopedic device maker, the company now plans to spend another $1 billion to buy LDR and grow its spine business. (MDD Perspectives)

Closing of $175M Asia VC fund underlines core opportunities in the medical device space

HONG KONG – In the midst of technological advancements that are disrupting the traditional health technology industry, some venture capital (VC) funds are reaping significant benefits by jumping into the medical device space in Asia in the formative days of the companies.

MDD Home   |   About MDD   |   Contact Us   |   Copyright Notices   |   Terms of Use   |   Privacy Statement   |   Free Alerts

Part of Thomson Reuters
thomsonreuters.com | lifesciences.thomsonreuters.com | BioWorld.com | medicaldevicedaily.com